We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Compared to Estimates, Phibro (PAHC) Q2 Earnings: A Look at Key Metrics
Read MoreHide Full Article
For the quarter ended December 2024, Phibro Animal Health (PAHC - Free Report) reported revenue of $309.3 million, up 23.8% over the same period last year. EPS came in at $0.54, compared to $0.33 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $298.7 million, representing a surprise of +3.55%. The company delivered an EPS surprise of +28.57%, with the consensus EPS estimate being $0.42.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Phibro performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Net Sales by Region- United States: $184.44 million compared to the $180.77 million average estimate based on two analysts. The reported number represents a change of +31.3% year over year.
Net Sales by Region- Asia Pacific: $19.56 million versus $18.16 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +32.5% change.
Net Sales by Region- Europe, Middle East and Africa: $32.59 million versus $39.86 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +10.4% change.
Net Sales by Region- Latin America and Canada: $72.67 million compared to the $75.27 million average estimate based on two analysts. The reported number represents a change of +11.5% year over year.
Net Sales- Animal Health: $229.42 million versus $221.51 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +32.5% change.
Net Sales- Mineral Nutrition: $63.25 million versus the three-analyst average estimate of $60.71 million. The reported number represents a year-over-year change of +3.1%.
Net Sales- Animal Health- Vaccines: $33.17 million compared to the $35.53 million average estimate based on three analysts. The reported number represents a change of +11.6% year over year.
Net Sales- Animal Health- MFAs and other: $150.34 million versus $143.18 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +47.5% change.
Net Sales- Animal Health- Nutritional specialties: $45.91 million versus the three-analyst average estimate of $42.80 million. The reported number represents a year-over-year change of +10.8%.
Net Sales- Performance Products: $16.59 million versus $16.35 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +7.1% change.
Adjusted EBITDA- Animal Health: $58.20 million versus the two-analyst average estimate of $51.55 million.
Adjusted EBITDA- Corporate: -$17.60 million versus -$18.40 million estimated by two analysts on average.
Shares of Phibro have returned +6.5% over the past month versus the Zacks S&P 500 composite's +1.7% change. The stock currently has a Zacks Rank #1 (Strong Buy), indicating that it could outperform the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Compared to Estimates, Phibro (PAHC) Q2 Earnings: A Look at Key Metrics
For the quarter ended December 2024, Phibro Animal Health (PAHC - Free Report) reported revenue of $309.3 million, up 23.8% over the same period last year. EPS came in at $0.54, compared to $0.33 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $298.7 million, representing a surprise of +3.55%. The company delivered an EPS surprise of +28.57%, with the consensus EPS estimate being $0.42.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Phibro performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Sales by Region- United States: $184.44 million compared to the $180.77 million average estimate based on two analysts. The reported number represents a change of +31.3% year over year.
- Net Sales by Region- Asia Pacific: $19.56 million versus $18.16 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +32.5% change.
- Net Sales by Region- Europe, Middle East and Africa: $32.59 million versus $39.86 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +10.4% change.
- Net Sales by Region- Latin America and Canada: $72.67 million compared to the $75.27 million average estimate based on two analysts. The reported number represents a change of +11.5% year over year.
- Net Sales- Animal Health: $229.42 million versus $221.51 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +32.5% change.
- Net Sales- Mineral Nutrition: $63.25 million versus the three-analyst average estimate of $60.71 million. The reported number represents a year-over-year change of +3.1%.
- Net Sales- Animal Health- Vaccines: $33.17 million compared to the $35.53 million average estimate based on three analysts. The reported number represents a change of +11.6% year over year.
- Net Sales- Animal Health- MFAs and other: $150.34 million versus $143.18 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +47.5% change.
- Net Sales- Animal Health- Nutritional specialties: $45.91 million versus the three-analyst average estimate of $42.80 million. The reported number represents a year-over-year change of +10.8%.
- Net Sales- Performance Products: $16.59 million versus $16.35 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +7.1% change.
- Adjusted EBITDA- Animal Health: $58.20 million versus the two-analyst average estimate of $51.55 million.
- Adjusted EBITDA- Corporate: -$17.60 million versus -$18.40 million estimated by two analysts on average.
View all Key Company Metrics for Phibro here>>>Shares of Phibro have returned +6.5% over the past month versus the Zacks S&P 500 composite's +1.7% change. The stock currently has a Zacks Rank #1 (Strong Buy), indicating that it could outperform the broader market in the near term.